Search

Your search keyword '"Naito, Tateaki"' showing total 590 results
Start Over Author "Naito, Tateaki" Language english
590 results on '"Naito, Tateaki"'

1. The efficacy and safety of anamorelin among patients with diabetes

Author

Ando, Kenju, Naito, Tateaki, Hamauchi, Satoshi, Miura, Keita, Nishibori, Yuichiro, Tonsho, Ayumi, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ryo, Ko, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Yamazaki, Kentaro, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

4. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing

Author

Wakuda, Kazushige, Morita, Meiko, Sekikawa, Motoki, Morikawa, Noboru, Miura, Keita, Doshita, Kosei, Iida, Yuko, Kodama, Hiroaki, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Muramatsu, Koji, Kawata, Takuya, Mori, Keita, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

5. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study

Author

Morikawa, Noboru, Naito, Tateaki, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Yabe, Michitoshi, Kodama, Hiroaki, Miura, Keita, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

12. Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Author

Nishio, Makoto, Ohe, Yuichiro, Ikeda, Satoshi, Yokoyama, Toshihide, Hayashi, Hidetoshi, Fukuhara, Tatsuro, Sato, Yuki, Tanaka, Hiroshi, Hotta, Katsuyuki, Sugawara, Shunichi, Daga, Haruko, Okamoto, Isamu, Kasahara, Kazuo, Naito, Tateaki, Li, Li, Gupta, Ravi G., Bushong, Judith, and Mizutani, Hideaki

Published
2023
Full Text
View/download PDF

16. Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

Author

Doshita, Kosei, Kenmotsu, Hirotsugu, Omori, Shota, Tabuchi, Yuya, Kawabata, Takanori, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Iida, Yuko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Kaneko, Takeshi, and Takahashi, Toshiaki

Published
2022
Full Text
View/download PDF

21. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.

Author

Doshita, Kosei, Naito, Tateaki, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Murakami, Haruyasu, Kenmotsu, Hirotsugu, and Takahashi, Toshiaki

Subjects
*THERAPEUTIC use of antineoplastic agents, *ANOREXIA nervosa treatment, *CANCER relapse, *ANTINEOPLASTIC agents, *TREATMENT effectiveness, *RETROSPECTIVE studies, *CANCER patients, *LUNGS, *DESCRIPTIVE statistics, *IMMUNE checkpoint inhibitors, *CANCER chemotherapy, *LUNG tumors, *ANOREXIA nervosa, *MEDICAL records, *ACQUISITION of data, *LUNG cancer, *PROGRESSION-free survival, *COMPARATIVE studies, *OVERALL survival, *PLATINUM, *DISEASE complications
Abstract

Background: Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy‐induced anorexia and therapeutic outcomes in patients with stage IV non‐small‐cell lung cancer undergoing platinum‐based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non‐small‐cell lung cancer treated with platinum‐based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy‐induced anorexia group. Chemotherapy‐induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression‐free and overall survival were used to measure treatment efficacy. Results: Chemotherapy‐induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non‐chemotherapy‐induced anorexia group. Progression‐free and overall survival were shorter in the chemotherapy‐induced anorexia group than in the non‐chemotherapy‐induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy‐induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non‐small‐cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy‐induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum‐based chemotherapy combined with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer.

Author

Morita, Meiko, Ono, Akira, Sekikawa, Motoki, Doshita, Kosei, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Isaka, Mitsuhiro, Ohde, Yasuhisa, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

26. Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer

Author

Okayama, Taro, Naito, Tateaki, Yonenaga, Yusuke, Ohashi, Takuya, Kitagawa, Midori, Mitsuhashi, Noriko, Ishi, Takeshi, Fuseya, Hiroshi, Aoyama, Takashi, Notsu, Akifumi, Mori, Keita, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Tanuma, Akira, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

27. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma

Author

Kodama, Hiroaki, Wakuda, Kazushige, Yabe, Michitoshi, Nishioka, Naoya, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Endo, Masahiro, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

28. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy

Author

Mamesaya, Nobuaki, Muramatsu, Koji, Yabe, Michitoshi, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Taichi, Miyawaki, Eriko, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, Sugino, Takashi, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

29. Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer.

Author

Kodama, Hiroaki, Murakami, Haruyasu, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Matsumoto, Shingo, Goto, Koichi, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Subjects
RNA analysis, DNA analysis, CYTOLOGY, CANCER treatment, POLYMERASE chain reaction, RETROSPECTIVE studies, DESCRIPTIVE statistics, FROZEN tissue sections, LUNG cancer, COLLECTION & preservation of biological specimens, SENSITIVITY & specificity (Statistics), SPECIALTY hospitals, SEQUENCE analysis, EPIDERMAL growth factor receptors
Abstract

Background: The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients with non‐small cell lung cancer (NSCLC). However, the suitability of cytology specimens as samples for the AmoyDx PLC panel remains unclear. We evaluated the performance of frozen cell pellets from cytology specimens (FCPs) in the Amoy 9‐in‐1 assay, a preapproval assay of the AmoyDx PLC panel. Methods: We retrospectively collected data of NSCLC patients enrolled in LC‐SCRUM‐Asia from the Shizuoka Cancer Center between September 2019 and May 2021. Results: A total of 49 cases submitted FCPs for evaluation of oncogenic driver alterations and were assessed using Amoy 9‐in‐1 and next‐generation sequencing (NGS) assays. The success rates of DNA and RNA analyses using the Amoy 9‐in‐1 were both 100%, compared with 86% and 45%, respectively, using NGS assays. Oncogenic driver alterations were detected in 27 (55%) and 23 (47%) patients using Amoy 9‐in‐1 and NGS, respectively. No inconsistent results were observed among 19 cases in which both assays showed successful detection. In the remaining 30 cases, 10 had inconsistent results: nine oncogenic driver alterations (3 MET, 2 ALK, 2 ROS1, and 2 KRAS) were detectable only in Amoy 9‐in‐1, and one epidermal growth factor receptor (EGFR) mutation was detectable only in NGS. Conclusion: FCPs can be successfully used in the AmoyDx PLC panel, with higher success rate compared with the NGS assay. The AmoyDx PLC panel may be an option in cases when insufficient tissue sample is available for the NGS assay. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

Author

Miyawaki, Taichi, Kenmotsu, Hirotsugu, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

33. Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Author

Inoue, Hiroto, Ono, Akira, Kawabata, Takanori, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Yasui, Kazuaki, Ogawa, Hirofumi, Onoe, Tsuyoshi, Endo, Masahiro, Harada, Hideyuki, and Takahashi, Toshiaki

Published
2020
Full Text
View/download PDF

37. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases

Author

Miyawaki, Eriko, Kenmotsu, Hirotsugu, Mori, Keita, Harada, Hideyuki, Mitsuya, Koichi, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Nakashima, Kazuhisa, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Endo, Masahiro, Nakasu, Yoko, Gon, Yasuhiro, and Takahashi, Toshiaki

Published
2019
Full Text
View/download PDF

39. Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.

Author

Iida, Yuko, Wakuda, Kazushige, Kawata, Takuya, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Yabe, Michitoshi, Kodama, Hiroaki, Miura, Keita, Morikawa, Noboru, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Gon, Yasuhiro, and Takahashi, Toshiaki

Subjects
BIOMARKERS, DRUG efficacy, CHROMOGRANINS, IMMUNE checkpoint inhibitors, NEUROENDOCRINE system, SPECIALTY hospitals, SMALL cell carcinoma, IMMUNOHISTOCHEMISTRY, CANCER chemotherapy, LUNG tumors, RETROSPECTIVE studies, ANTINEOPLASTIC agents, CANCER treatment, PROGRESSION-free survival, OVERALL survival, EVALUATION
Abstract

Background: Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on the efficacy of ICIs based on conventional immunohistochemical neuroendocrine (NE) markers (synaptophysin, chromogranin A, and neural cell adhesion molecule [NCAM]). In the present study, we aimed to analyze the relationship between the expression of immunohistochemical NE markers and the efficacy of ICIs in patients with extensive disease (ED)‐SCLC, to assess whether conventional NE markers are predictive of ICIs. Methods: Patients with untreated ED‐SCLC who received first‐line therapy at the Shizuoka Cancer Center between November 2002 and July 2021 were retrospectively reviewed. We evaluated the efficacy of first‐line chemotherapy according to the expression status of each immunohistochemical NE marker in patients treated with ICI plus chemotherapy (ICI‐chemo group) and with chemotherapy alone (chemo group). Results: A total of 227 patients were included in the ICI‐chemo and chemo groups, respectively. The progression‐free survival (PFS) tended to be better in patients in the ICI‐chemo group than those treated with chemotherapy alone in patients with NE marker‐positive SCLC. In particular, it was statistically significant in patients with chromogranin A‐positive SCLC (p = 0.036). In patients with NE marker‐negative SCLC, no significant differences were observed in PFS between the two groups. There were no significant differences in overall survival (OS), regardless of the expression of any conventional NE marker. Conclusion: Our study suggests that the efficacy of ICIs in addition to chemotherapy may be poor in patients with NE marker‐negative SCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non–Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing

Author

Isaka, Mitsuhiro, Serizawa, Masakuni, Kenmotsu, Hirotsugu, Koh, Yasuhiro, Takahashi, Shoji, Maniwa, Tomohiro, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Endo, Masahiro, Abe, Masato, Hayashi, Isamu, Nakajima, Takashi, Yamamoto, Nobuyuki, Takahashi, Toshiaki, and Ohde, Yasuhisa

Published
2017
Full Text
View/download PDF

48. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer.

Author

Sekikawa, Motoki, Murakami, Haruyasu, Morita, Meiko, Doshita, Kosei, Miura, Keita, Kodama, Hiroaki, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Chiba, Hirofumi, and Takahashi, Toshiaki

Subjects
LUNG cancer, ANTHRACYCLINES, GRANULOCYTE-colony stimulating factor, FEBRILE neutropenia, CANCER chemotherapy, ANTINEOPLASTIC agents, RETROSPECTIVE studies, TREATMENT effectiveness, CANCER patients, PROGRESSION-free survival, OVERALL survival, EVALUATION
Abstract

Background: Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and efficacy of AMR with primary prophylactic pegfilgrastim (P‐PEG) have not been sufficiently evaluated. In this study, we evaluated the safety and efficacy of AMR with or without P‐PEG as second‐line chemotherapy for SCLC. Methods: We retrospectively reviewed patients with SCLC who received AMR as second‐line chemotherapy at Shizuoka Cancer Center, between December 2014 and November 2021. Based on presence/absence of P‐PEG in their regimen, patients (n = 60) were divided into P‐PEG (n = 21) and non‐P‐PEG groups, and their clinical outcomes were evaluated. Results: Median of AMR treatment cycles was five (range: 1–39 cycles) in P‐PEG group and four (range: 1–15 cycles) in non‐P‐PEG group. The incidence of FN (4.8% vs. 30.8%; p = 0.02) and AMR dose reduction because of adverse events (4.8% vs. 25.6%; p = 0.08) were lower in the P‐PEG group than in the non‐P‐PEG group. The objective response rates were 52.4% and 30.8%, and median progression‐free and overall survival were 4.7 and 3.0 months, and 9.6 and 6.8 months, in the P‐PEG and non‐P‐PEG groups, respectively. Conclusions: AMR with P‐PEG as second‐line chemotherapy for SCLC reduced the incidence of FN at a maintained AMR dose intensity and was associated with favorable tumor responses and survival outcomes. P‐PEG should be considered for patients treated with AMR for SCLC including refractory relapsed SCLC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

Author

Yokota, Tomoya, Bendell, Johanna, LoRusso, Patricia, Tsushima, Takahiro, Desai, Ved, Kenmotsu, Hirotsugu, Watanabe, Junichiro, Ono, Akira, Murugesan, Bhavani, Silva, Joseph, Naito, Tateaki, Greenberg, Jonathan, Kumar, Prasanna, Wang, Yibin, Jikoh, Takahiro, Shiga, Ryota, Hyman, David M., Ho, Alan Loh, Spriggs, David R., Schwartz, Gary K., and Gounder, Mrinal M.

Published
2018
Full Text
View/download PDF

50. Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Author

Inoue, Hiroto, Ono, Akira, Kawabata, Takanori, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Yasui, Kazuaki, Ogawa, Hirofumi, Onoe, Tsuyoshi, Endo, Masahiro, Harada, Hideyuki, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results